Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

Article Details

Citation

Copy to clipboard

Viani RM

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

HIV AIDS (Auckl). 2010;2:141-9. Epub 2010 Jun 28.

PubMed ID

22096392 [ View in PubMed

]

Abstract

Etravirine is an oral diarylpyrimidine compound, a second-generation human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) with expanded antiviral activity against NNRTI-resistant HIV-1, to be used in combination therapy for treatment-experienced patients. Compared with first-generation NNRTIs, etravirine has a high genetic barrier to resistance, and is better tolerated without the neuropsychiatric and hepatic side effects of efavirenz and nevirapine, respectively. Its safety profile is comparable to placebo with the exception of rash, which has been mild and self-limited in the great majority of patients. In phase III clinical trials among treatment-experienced patients harboring NNRTI-resistant HIV-1, etravirine in combination with an optimized background regimen (OBR) that included ritonavir-boosted darunavir demonstrated superior antiviral activity than the control OBR. In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Etravirine	Cytochrome P450 2C19	Protein	Humans	Unknown	Substrate Inhibitor	Details